COMPANY RESEARCHThe website lists NanoBRET/TR-FRET/SPR and HiBiT/JESS platforms for permeability, target engagement, ternary complexes, and quantitative degradation kinetics.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
The website lists NanoBRET/TR-FRET/SPR and HiBiT/JESS platforms for permeability, target engagement, ternary complexes, and quantitative degradation kinetics.
Discloses ASD, spray-dried dispersion, hot-melt extrusion, and modified-release formulation development, supported by analytical data and early PK feedback for clinical manufacturing.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| Degrader design, biology, DMPK, and translational evaluation | Program-dependent / not disclosed · Determined by the collaboration program | Platform / services | This record does not claim platform-wide human validation |
| Formulation development / contract manufacturing capabilities | Defined by the client project · Defined by the client project | Services / platform | Service pages do not establish human evidence for every project |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
Amphista announced an ASH oral presentation on AMX-883-mediated BRD9 degradation, describing disruption of hematopoietic transcriptional programs, myeloid differentiation, and reduced leukemic stem-cell frequency in experimental work. A separate abstract outlines the ongoing Phase 1 BRAMLIE study in AML and high-risk myelodysplastic syndrome. The announcement does not establish clinical efficacy for AMX-883.
Nurix announced updated Phase 1a/1b findings for its oral BTK degrader bexobrutideg (NX-5948) in relapsed or refractory CLL/SLL. The ASH presentation will include patients previously exposed to covalent BTK inhibitors and data at the recommended Phase 2 dose of 600 mg once daily. The release describes durable activity without providing numerical response rates.
Phillips Medisize announced an investment to acquire the complete footprint of its Chippenham site in England, strengthening its Global Inhalation Center of Excellence alongside Cambridge. Building on the 2025 Vectura acquisition, the site supports drug-device formulation development and early- and late-stage clinical supplies. The announcement links the investment to anticipated growth in complex inhaled therapies.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.
